Biotech Investing argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
Biotech Investing argenx Announces VYVGART SC Prefilled Syringe for Self-Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada
Biotech Investing argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
Biotech Investing argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025
Biotech Investing argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia
Surface Sampling at Smart Creek Project Yields High-Grade Mineralization with up to 102 g/t Au, up to 23% Cu and up to 3810 g/t Ag
Skyharbour Announces Additional Uranium Property Staking Increasing Total Portfolio to Over 662,000 Hectares in the Athabasca Basin, Saskatchewan
